Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 08:00 ET | Source: Septerna, Inc.

Septerna to Present at TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today...
February 18, 2025 08:00 ET | Source: Septerna, Inc.

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures...
January 06, 2025 07:00 ET | Source: Septerna, Inc.

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug...
December 18, 2024 08:00 ET | Source: Septerna, Inc.

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey...
November 20, 2024 07:00 ET | Source: Septerna, Inc.

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small...
October 30, 2024 16:41 ET | Source: Septerna, Inc.

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral...
October 24, 2024 21:47 ET | Source: Septerna, Inc.

Septerna Prices Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral...